U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06891742) titled 'Phase I Study of OriC902 in Treatment of Advanced HCC' on Feb. 24.
Brief Summary: This is a Phase I clinical study evaluating the safety, pharmacokinetics, and initial efficacy of a GPC3-targeted chimeric antigen receptor autologous T cell injection (OriC902) in GPC3-positive advanced hepatocellular carcinoma (HCC) subjects
Study Start Date: Feb. 24
Study Type: INTERVENTIONAL
Condition:
HCC
Intervention:
DRUG: OriC902
Whole peripheral blood mononuclear cells are extracted from patients (or donors) through leukocyte separation, and then the required T cell subsets are isolated, which will become the basis for the subsequent p...